|
|
Volumn 14, Issue , 2002, Pages S57-S64
|
|
IC351 (tadalafil, Cialis): Update on clinical experience
a
|
|
Author keywords
Cyclic guanosine monophosphate; Erectile dysfunction; IC351; Pharmacotherapy; Phosphodiesterase 5 inhibition; Tadalafil
|
|
Indexed keywords
CARBOLINES;
CLINICAL TRIALS;
HUMANS;
IMPOTENCE;
MALE;
PHOSPHODIESTERASE INHIBITORS;
CYCLIC GMP;
PHOSPHODIESTERASE;
PHOSPHODIESTERASE I;
PHOSPHODIESTERASE III;
PHOSPHODIESTERASE INHIBITOR;
PHOSPHODIESTERASE IV;
PHOSPHODIESTERASE IX;
PHOSPHODIESTERASE V;
PHOSPHODIESTERASE VI;
PHOSPHODIESTERASE VII;
PHOSPHODIESTERASE VIII;
PHOSPHODIESTERASE X;
PLACEBO;
SILDENAFIL;
SPLEEN EXONUCLEASE;
TADALAFIL;
UNCLASSIFIED DRUG;
VARDENAFIL;
BACKACHE;
CLINICAL TRIAL;
CONFERENCE PAPER;
DIABETES MELLITUS;
DISEASE SEVERITY;
DOSE RESPONSE;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG SELECTIVITY;
DYSPEPSIA;
ERECTILE DYSFUNCTION;
HEADACHE;
HUMAN;
MALE;
MYALGIA;
PENIS ERECTION;
PRIORITY JOURNAL;
SEXUAL INTERCOURSE;
TREATMENT OUTCOME;
|
|
EID: 0036197133
PISSN: 09559930
EISSN: None
Source Type: Journal
DOI: 10.1038/sj.ijir.3900807 Document Type: Article |
|
Times cited : (103)
|
|
References (12)
|
